The Russian single-component coronavirus vaccine Sputnik Light (the first component of the Sputnik V vaccine) has received approval for use in Iran, the Russian Direct Investment Fund (RDIF) announced.
"The Russian Direct Investment Fund (RDIF, a sovereign wealth fund of the Russian Federation) announces that the ministry of health of the Islamic Republic of Iran has approved the use of the Russian single-component vaccine against the coronavirus Sputnik Light," the statement reads.
The two-component Sputnik V vaccine was also approved in Iran in January 2021.
Sputnik Light has demonstrated high safety and efficacy during vaccination of the population in a number of countries. In particular, data from the ministry of health of the province of Buenos Aires (Argentina) showed a 78.6-83.7% efficacy of the Sputnik Light vaccine in vaccinating the elderly. In Paraguay, according to the country's ministry of health, the effectiveness of the drug was 93.5% during mass vaccination," said the fund.
Sputnik Light is currently used not only independently but is also studied in combination with drugs from other manufacturers. RDIF was the first in the world to initiate a partnership with other vaccine manufacturers to jointly study combinations of the first component of Sputnik V with foreign drugs.
Similar studies are currently underway in Argentina, the UAE, Azerbaijan, and other countries.
GSV "Russia - Islamic World"
Photo: Creative Commons
Based on materials from RIA Novosti